

Subject Index

A

Allopurinol
renal calculi 8: 67
Antibacterial agents
therapeutic efficacy
meningitis 8: 30-37, 42-48
Anticonvulsants
meningitis 8: 38

B

Baclofen 8: 1-14
absorption 8: 10
animal pharmacology 8: 8
clinical experimental studies 8: 2-3
contra-indications 8: 12
distribution 8: 10-12
excretion 8: 11
dosage 8: 13
metabolism 8: 11
mode of action 8: 8-10
overdosage 8: 13

pharmacokinetics 8: 10-11
precautions 8: 12-13
side-effects 8: 11-12
spasticity 8: 4-8
therapeutic trials 8: 4-8
open trials 8: 5-8
placebo-controlled 8: 4-5
Bacterial meningitis
see meningitis

C

Calcium stones
see Renal calculi
Cerebrospinal fluid
meningitis 8: 25
Corticosteroids
meningitis 8: 38
Corticosteroids: topical
adverse reactions 8: 70-77
adverse reactions, local 8: 71-75
allergy 8: 75
atrophy 8: 74-75

Subject Index

A

Allopurinol
renal calculi 8: 67
Antibacterial agents
therapeutic efficacy
meningitis 8: 30-37, 42-48
Anticonvulsants
meningitis 8: 38

B

Baclofen 8: 1-14
absorption 8: 10
animal pharmacology 8: 8
clinical experimental studies 8: 2-3
contra-indications 8: 12
distribution 8: 10-12
excretion 8: 11
dosage 8: 13
metabolism 8: 11
mode of action 8: 8-10
overdosage 8: 13

pharmacokinetics 8: 10-11
precautions 8: 12-13
side-effects 8: 11-12
spasticity 8: 4-8
therapeutic trials 8: 4-8
open trials 8: 5-8
placebo-controlled 8: 4-5
Bacterial meningitis
see meningitis

C

Calcium stones
see Renal calculi
Cerebrospinal fluid
meningitis 8: 25
Corticosteroids
meningitis 8: 38
Corticosteroids: topical
adverse reactions 8: 70-77
adverse reactions, local 8: 71-75
allergy 8: 75
atrophy 8: 74-75

Subject Index

79

- face lesions 8: 71-72
- hypertrichosis 8: 75
- infection 8: 73-74
- ulceration 8: 75
- adverse reactions, systemic 8: 75-77
- Counter-immunoelectrophoresis 8: 26
- Cystine stones
 - see renal calculi
- D**
- Drug reactions, adverse
 - baclofen 8: 11-12
 - corticosteroids 8: 70-77
- G**
- Glucose levels
 - meningitis 8: 25-26
- H**
- H. influenza* meningitis
 - see meningitis
- Hyperoxaluria
 - treatment 8: 68-69
- Hypertrichosis
 - due to corticosteroids 8: 75
- M**
- Magnesium ammonium phosphate stones
 - see renal calculi
- Meningitis
 - age incidence 8: 19-21
 - causative organisms 8: 19-21
 - mortality and morbidity rates 8: 17-19
 - neonatal meningitis 8: 46-48
 - persistent fever 8: 41
 - pre-disposing causes 8: 22-23
 - altered immune state 8: 23
 - CNS congenital anomalies 8: 22
 - primary infection elsewhere 8: 22-23
 - sex 8: 22
 - socio-economic status 8: 22
 - rare meningitides 8: 48
 - rehabilitation 8: 41-42
- Meningitis: diagnosis 8: 23-29
 - cerebrospinal fluid examination 8: 25
 - clinical presentation 8: 23-25
 - counter-immunoelectrophoresis 8: 26
 - culture 8: 25
 - differential cell count 8: 25
 - enzyme estimations 8: 26
 - glucose determination 8: 25-26
 - immunoglobulin levels 8: 28
 - limulus lysate 8: 28
 - nitroblue tetrazolium dye test 8: 28
 - prior antibiotic treatment 8: 28-29
 - protein level 8: 26
- Meningitis: treatment 8:
 - general considerations 8: 29-37
 - bactericidal and bacteriostatic drugs 8: 30-33
 - bacteriological considerations 8: 29-33
 - pharmacokinetics 8: 33-37
 - sensitivity of infecting organisms 8: 29-30
 - initial treatment 8: 37-38
 - anticonvulsants 8: 38
 - cerebral oedema 8: 38
 - choice of antibacterial drug 8: 37
 - corticosteroids 8: 38
 - shock 8: 38
 - monitoring its effectiveness 8: 40-41
 - specific infections: treatment 8: 42-46
 - H. influenza* meningitis 8: 42-44
 - meningococcal meningitis 8: 44-45
 - pneumococcal meningitis 8: 45-46
 - staphylococcal meningitis 8: 46
 - streptococcal meningitis 8: 46
 - supportive treatment 8: 39-40
 - accompanying infection 8: 39
 - biochemical abnormalities 8: 40
 - general measures 8: 39
 - hydrocephalus 8: 40
 - subdural effusions 8: 39-40
- Meningococcal meningitis
 - see meningitis
- Multiple sclerosis
 - see sclerosis, multiple
- N**
- Neonate
 - meningitis 8: 46-48
- Nitroblue tetrazolium dye test
 - meningitis 8: 28
- P**
- D-Penicillamine
 - renal calculi 8: 68
- Pneumococcal meningitis
 - see meningitis
- Pregnancy
 - bacteriuria 8: 59
- R**
- Renal calculi
 - aetiology 8: 62-63
 - pathogenesis 8: 63-64
 - treatment 8: 62-69

Subject Index

80

treatment: general 8: 62-65
 hydration control 8: 65
 urinary infection control 8: 65
 role of surgery 8: 64
treatment: specific 8: 65-69
 calcium stones 8: 65-67
 cystine stones 8: 68
 hyperoxaluria 8: 68-69
 magnesium ammonium phosphate stones 8: 67
 uric acid stones 8: 67-68

S

Sclerosis, multiple
 baclofen 8: 4-8
Spasticity
 baclofen 8: 4-8

U

Uric acid stones
 see renal calculi
Urinary tract infection 8: 54-61
 diagnosis 8: 54-56
 suprapubic aspiration 8: 55-56
 urine specimen 8: 55
 follow-up 8: 61
 treatment 8: 56-59
 acute attack 8: 56-57
 in the male 8: 59
 in pregnancy 8: 59
 recurrent attacks 8: 57-59
 in renal impairment 8: 59
 who and when to investigate 8: 59-61
Urine tests 8: 55

**Progress in Biochemical
Pharmacology**

Series Editor: *R. Paoletti* (Milan)

Drugs and the Kidney

**Progress in Biochemical
Pharmacology, Vol. 9**

Series Editor: *R. Paoletti* (Milan)

Drugs and the Kidney

Volume Editor:

K. David G. Edwards (Sydney)

XI + 278 p., 64 fig., 43 tab., 1974

SFr. 110.- / US \$ 40.25 / DM 105.- / £ 16.00

ISBN 3-8055-1693-2

Biochemical pharmacologists, although leaders in the field of contemporary scientific research, have not concentrated greatly on the kidney, and nephrologists have been trained only infrequently in biochemical pharmacology. In 1972, 'Drugs Affecting Kidney Function and Metabolism', Volume 7 in this series, was published in order to begin to bridge the gap. The present book, Volume 9, which supplements Volume 7, arose out of the 4th Kanematsu Conference on the Kidney, Sydney, which was planned as a forum for new work on 'Drugs and the Kidney'. Twenty selected papers in the present volume discuss new findings on drugs and single nephrons; renovascular pharmacology (including the actions of dopamine, propranolol, cyclophosphamide, antihyperlipidaemic agents and antilymphocyte globulin); prevention of fibrin deposition; drugs affecting urate transport and metabolism; drug interactions; and recent advances in therapy of chronic renal failure.



S. Karger
Basel · München · Paris · London
New York · Sydney

Contents:

Section I: Drugs and Single Nephrons

Contributions by: *S.E. Bradley and J.B. Coelho* (New York, N.Y.), *T.O. Morgan* (Melbourne)

Section II: Renovascular Pharmacology

Contributions by: *W.J. Louis and R. Sampson* (Melbourne), *G.S. Stokes, M.A. Weber, I.R. Thornell, L.M. Stoker and E.F. Sebel* (Sydney), *A.N. Whitaker* (Brisbane), *L.S. Ibels, A.A. Palmer, J.F. Mahony, J.H. Stewart, G.J. Schapel, K.D.G. Edwards, F.C. Neale, A.G.R. Sheil, D.C. Mears, G.E. Kelly and J.A. Charlesworth* (Sydney)

Section III: Drug Interactions

Contributions by: *E.G. McQueen* (Dunedin), *S. Kalowski, R.S. Nanra, T.H. Mathew and P. Kincaid-Smith* (Melbourne)

**Section IV: Drugs Affecting Urate
Transport and Metabolism**

Contributions by: *B.T. Emmerson* (Brisbane), *P.C. Farell* (Seattle, Wash.), *G.M. Fanelli* (West Point, Pa.), *W.J. O'Sullivan* (Sydney)

**Section V: Therapy in Chronic Renal
Failure**

Contributions by: *A. Goulding and R.O.H. Irvine* (Dunedin), *J.K. Dawborn* (Melbourne), *C.R. Blagg, J.E. Vizzo, W.B. Jensen, J.J. Cole, M.R. Kelly, R.C. Davidson, P.L. Hoover and B.H. Scribner* (Seattle, Wash.)

General Information

Publication data: Two volumes of *Drugs* are published annually. Each volume comprises six 80-page issues. Subscription price per volume SFr. 135. - / US \$49.00 / DM128. - / £19.60 including postage. Multiple subscription rates on request. *Drugs* is published by Australasian Drug Information Services Pty. Ltd., 559 Sydney Road, Seaforth, N.S.W. Australia.

Subject index: Each issue has its own comprehensive subject index which is cumulated in issue No. 6 of the second volume in each year.

Editorial matter is prepared by our own professionally qualified editorial staff and by honorary specialist consultants from all fields of medicine. While great care has been taken in compiling and checking the information contained in *Drugs*, the publisher cannot accept any responsibility for errors or omissions. The inclusion or exclusion of any product does not mean that the publisher advocates or rejects its use either generally or in any particular field or fields.

Drug nomenclature: Approved names of the British Pharmacopoeia Commission are used throughout the text. When the Commission has not adopted a name for the drug under discussion, the United States Adopted Name (USAN - United States Pharmacopoeial Convention Inc) or the International Non-Proprietary Name (INN - WHO) is used. When available, all three names are given at the head of the evaluations on new drugs and review article sections, and elsewhere in the text as appropriate. Other synonyms (e.g. research code names of new drugs) are also given.

Correspondence: Letters to the editor are welcomed. They should be submitted in duplicate type-written on one side of the paper only and double-spaced with a wide margin. They should be of reasonable length and written in English. Letters will be published if found suitable and will be subject to editorial review and possible abridgement.

Manuscripts: Information on the preparation of manuscripts will be provided to authors.

Copyright © 1974 Australasian Drug Information Services Pty Limited. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying or recording or by any information storage and retrieval system, without permission in writing from the publishers.

Subscription

Subscription orders can be placed with any bookstore or direct with the distributors S. Karger AG, Arnold-Böcklin-Strasse 25, CH-4011 Basel (Switzerland), or else with the following:

Subscription Order Form	
Please enter my subscription for <i>Drugs</i> beginning with	
<input type="checkbox"/> Vol. 1, 1971	<input type="checkbox"/> Vol. 4, 1972 <input type="checkbox"/> Vol. 7, 1974
<input type="checkbox"/> Vol. 2, 1971	<input type="checkbox"/> Vol. 5, 1973 <input type="checkbox"/> Vol. 8, 1974
<input type="checkbox"/> Vol. 3, 1972	<input type="checkbox"/> Vol. 6, 1973
Name _____	
Title _____	
Address _____	
City _____	
State/Zip _____	
Bundesrepublik Deutschland: S. Karger GmbH, Postfach 2, D-8034 Germering/München	
France: S. Karger S.A., 42bis, Bd de La Tour-Maubourg, F-75 Paris 7e	
Great Britain: John Wiley and Sons Ltd., Baffins Lane, Chichester, Sussex	
USA: Albert J. Phiebig Inc., US Representative of S. Karger, P.O. Box 352, White Plains, NY 10602	
Australia: Australasian Drug Information Services Pty.Ltd., Agents in Australasia for S. Karger, P.O. Box 194, Balgowlah/Sydney, NSW 2093	
New Zealand: Australasian Drug Information Services Pty.Ltd., New Zealand Office, P.O. Box 30-049, Takapuna North/Auckland 9	

